GAIN THERAPEUTICS, INC Interest Income (Expense), Nonoperating, Net
GAIN THERAPEUTICS, INC (GANX) reported Interest Income (Expense), Nonoperating, Net of $61.06 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNonoperatingNet · last filed 2026-08-11
- GAIN THERAPEUTICS, INC interest income (expense), nonoperating, net for the quarter ending 2026-06-30 was $61.06K, a 43.45% increase year-over-year.
- GAIN THERAPEUTICS, INC interest income (expense), nonoperating, net for the quarter ending 2026-03-31 was $93.05K, a 130.25% increase year-over-year.
- GAIN THERAPEUTICS, INC interest income (expense), nonoperating, net for the quarter ending 2025-12-31 was $83.34K, a 60.71% increase year-over-year.
- GAIN THERAPEUTICS, INC interest income (expense), nonoperating, net for the quarter ending 2025-09-30 was $78.07K, a 25.93% decline year-over-year.
- GAIN THERAPEUTICS, INC interest income (expense), nonoperating, net for fiscal 2025 was $244.39K, a 31.56% decline from fiscal 2024.
- GAIN THERAPEUTICS, INC interest income (expense), nonoperating, net for fiscal 2024 was $357.10K, a 27.75% decline from fiscal 2023.
- GAIN THERAPEUTICS, INC interest income (expense), nonoperating, net for fiscal 2023 was $494.23K.
| Period end | Interest Income (Expense), Nonoperating, Net 3 month | Interest Income (Expense), Nonoperating, Net 6 month | Interest Income (Expense), Nonoperating, Net 9 month | Interest Income (Expense), Nonoperating, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $61.06K 10-Q · filed 2026-08-11 | $154.11K 10-Q · filed 2026-08-11 | $237.45K derived: sum of 3 quarters · filed 2026-08-11 | $315.53K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $93.05K 10-Q · filed 2026-05-11 | $176.39K derived: sum of 2 quarters · filed 2026-05-11 | $254.47K derived: sum of 3 quarters · filed 2026-05-11 | $297.03K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $83.34K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $161.41K derived: sum of 2 quarters · filed 2026-03-26 | $203.98K derived: sum of 3 quarters · filed 2026-08-11 | $244.39K 10-K · filed 2026-03-26 |
| 2025-09-30 | $78.07K 10-Q · filed 2025-11-12 | $120.64K derived: sum of 2 quarters · filed 2026-08-11 | $161.06K 10-Q · filed 2025-11-12 | $212.91K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $42.57K 10-Q · filed 2026-08-11 | $82.98K 10-Q · filed 2026-08-11 | $134.84K derived: sum of 3 quarters · filed 2026-08-11 | $240.24K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $40.41K 10-Q · filed 2026-05-11 | $92.27K derived: sum of 2 quarters · filed 2026-05-11 | $197.68K derived: sum of 3 quarters · filed 2026-05-11 | $282.21K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $51.86K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $157.26K derived: sum of 2 quarters · filed 2026-03-26 | $241.79K derived: sum of 3 quarters · filed 2026-03-26 | $357.10K 10-K · filed 2026-03-26 |
| 2024-09-30 | $105.41K 10-Q · filed 2025-11-12 | $189.94K derived: sum of 2 quarters · filed 2025-11-12 | $305.24K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $84.53K 10-Q · filed 2025-08-12 | $199.83K 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $115.30K 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $494.23K 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |